Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial.
Pouyiourou M, Kraft BN, Wohlfromm T, Stahl M, Kubuschok B, Löffler H, Hacker UT, Hübner G, Weiss L, Bitzer M, Ernst T, Schütt P, Hielscher T, Delorme S, Kirchner M, Kazdal D, Ball M, Kluck K, Stenzinger A, Bochtler T, Krämer A. Pouyiourou M, et al. Among authors: schutt p. Nat Commun. 2023 Oct 24;14(1):6761. doi: 10.1038/s41467-023-42400-5. Nat Commun. 2023. PMID: 37875494 Free PMC article. Clinical Trial.
Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass).
Grünwald V, Ivanyi P, Zschäbitz S, Wirth M, Staib P, Schostak M, Dargatz P, Müller L, Metz M, Bergmann L, Steiner T, Welslau M, Lorch A, Rafiyan R, Hellmis E, Darr C, Schütt P, Meiler J, Kretz T, Loidl W, Flörcken A, Mänz M, Hinke A, Hartmann A, Grüllich C. Grünwald V, et al. Among authors: schutt p. Eur Urol. 2023 Dec;84(6):571-578. doi: 10.1016/j.eururo.2023.09.004. Epub 2023 Sep 26. Eur Urol. 2023. PMID: 37758574 Clinical Trial.
Production and separation of positron emitters for hadron therapy at FRS-Cave M.
Haettner E, Geissel H, Franczak B, Kostyleva D, Purushothaman S, Tanaka YK, Amjad F, Boscolo D, Dickel T, Graeff C, Hessler C, Hornung C, Kazantseva E, Kuzminchuk N, Morrissey D, Mukha I, Pietri S, Rocco E, Roy P, Roesch H, Schuy C, Schütt P, Weber U, Weick H, Zhao J, Durante M, Parodi K, Scheidenberger C; Super-FRS Experiment Collaboration. Haettner E, et al. Among authors: schutt p. Nucl Instrum Methods Phys Res B. 2023 Aug;541:114-116. doi: 10.1016/j.nimb.2023.04.026. Epub 2023 May 19. Nucl Instrum Methods Phys Res B. 2023. PMID: 37265512 Free PMC article.
Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP).
Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska-Lange A, Schütt P, Steger F, Brückl WM, Christoph DC. Faehling M, et al. Among authors: schutt p. Lung Cancer. 2020 Dec;150:114-122. doi: 10.1016/j.lungcan.2020.10.006. Epub 2020 Oct 21. Lung Cancer. 2020. PMID: 33126091
43 results